Figure 2.

Effects of EGFR inhibitor (Gefitinib) on malignant phenotypes in GALNT2-knockdown AGS cells. Cell viability was analyzed by MTT assay in AGS cells or MKN28 cells. The results were graphed after standardization by siC group treated with DMSO (Day 1) to 1.0. There were no significant differences of cell viability between siGALNT2 and siC group treated with either DMSO or gefitinib. GALNT2-knockdown increased the number of migrated (B, E)/invaded (C, F) cells compared with that of siC group, but the addition of Gefitinib (1 μΜ) mitigated these changes. The number of migrated/invaded cells was calculated at 4 random fields per experiment (×100) and expressed as fold change of siC without gefitinib treatment. Results are represented as mean ± S.D. from three independent experiments. *P < 0.05. (A-C, AGS cells; D-F, MKN28 cells).